Cargando…
Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials
INTRODUCTION: Catecholamines are the most used vasopressors in vasodilatory shock. However, the development of adrenergic hyposensitivity and the subsequent loss of catecholamine pressor activity necessitate the search for other options. Our aim was to evaluate the effects of vasopressin and its ana...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580743/ https://www.ncbi.nlm.nih.gov/pubmed/22889256 http://dx.doi.org/10.1186/cc11469 |
_version_ | 1782260320944783360 |
---|---|
author | Serpa Neto, Ary Nassar, Antônio P Cardoso, Sérgio O Manetta, José A Pereira, Victor GM Espósito, Daniel C Damasceno, Maria CT Russell, James A |
author_facet | Serpa Neto, Ary Nassar, Antônio P Cardoso, Sérgio O Manetta, José A Pereira, Victor GM Espósito, Daniel C Damasceno, Maria CT Russell, James A |
author_sort | Serpa Neto, Ary |
collection | PubMed |
description | INTRODUCTION: Catecholamines are the most used vasopressors in vasodilatory shock. However, the development of adrenergic hyposensitivity and the subsequent loss of catecholamine pressor activity necessitate the search for other options. Our aim was to evaluate the effects of vasopressin and its analog terlipressin compared with catecholamine infusion alone in vasodilatory shock. METHODS: A systematic review and meta-analysis of publications between 1966 and 2011 was performed. The Medline and CENTRAL databases were searched for studies on vasopressin and terlipressin in critically ill patients. The meta-analysis was limited to randomized controlled trials evaluating the use of vasopressin and/or terlipressin compared with catecholamine in adult patients with vasodilatory shock. The assessed outcomes were: overall survival, changes in the hemodynamic and biochemical variables, a decrease of catecholamine requirements, and adverse events. RESULTS: Nine trials covering 998 participants were included. A meta-analysis using a fixed-effect model showed a reduction in norepinephrine requirement among patients receiving terlipressin or vasopressin infusion compared with control (standardized mean difference, -1.58 (95% confidence interval, -1.73 to -1.44); P < 0.0001). Overall, vasopressin and terlipressin, as compared with norepinephrine, reduced mortality (relative risk (RR), 0.87 (0.77 to 0.99); P = 0.04). Vasopressin compared with norepinephrine decreased mortality in adult patients (RR, 0.87 (0.76 to 1.00); P = 0.05) and in patients with septic shock (42.5% vs. 49.2%, respectively; RR, 0.87 (0.75 to 1.00); P = 0.05; number needed to treat, 1 to 15). There was no difference in adverse events between the vasopressin and control groups (RR, 0.98 (0.65 to 1.47); P = 0.92). CONCLUSIONS: Vasopressin use in vasodilatory shock is safe, associated with reduced mortality, and facilitates weaning of catecholamines. In patients with septic shock, use of vasopressin compared with norepinephrine may also decrease mortality. |
format | Online Article Text |
id | pubmed-3580743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35807432013-02-26 Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials Serpa Neto, Ary Nassar, Antônio P Cardoso, Sérgio O Manetta, José A Pereira, Victor GM Espósito, Daniel C Damasceno, Maria CT Russell, James A Crit Care Research INTRODUCTION: Catecholamines are the most used vasopressors in vasodilatory shock. However, the development of adrenergic hyposensitivity and the subsequent loss of catecholamine pressor activity necessitate the search for other options. Our aim was to evaluate the effects of vasopressin and its analog terlipressin compared with catecholamine infusion alone in vasodilatory shock. METHODS: A systematic review and meta-analysis of publications between 1966 and 2011 was performed. The Medline and CENTRAL databases were searched for studies on vasopressin and terlipressin in critically ill patients. The meta-analysis was limited to randomized controlled trials evaluating the use of vasopressin and/or terlipressin compared with catecholamine in adult patients with vasodilatory shock. The assessed outcomes were: overall survival, changes in the hemodynamic and biochemical variables, a decrease of catecholamine requirements, and adverse events. RESULTS: Nine trials covering 998 participants were included. A meta-analysis using a fixed-effect model showed a reduction in norepinephrine requirement among patients receiving terlipressin or vasopressin infusion compared with control (standardized mean difference, -1.58 (95% confidence interval, -1.73 to -1.44); P < 0.0001). Overall, vasopressin and terlipressin, as compared with norepinephrine, reduced mortality (relative risk (RR), 0.87 (0.77 to 0.99); P = 0.04). Vasopressin compared with norepinephrine decreased mortality in adult patients (RR, 0.87 (0.76 to 1.00); P = 0.05) and in patients with septic shock (42.5% vs. 49.2%, respectively; RR, 0.87 (0.75 to 1.00); P = 0.05; number needed to treat, 1 to 15). There was no difference in adverse events between the vasopressin and control groups (RR, 0.98 (0.65 to 1.47); P = 0.92). CONCLUSIONS: Vasopressin use in vasodilatory shock is safe, associated with reduced mortality, and facilitates weaning of catecholamines. In patients with septic shock, use of vasopressin compared with norepinephrine may also decrease mortality. BioMed Central 2012 2012-08-14 /pmc/articles/PMC3580743/ /pubmed/22889256 http://dx.doi.org/10.1186/cc11469 Text en Copyright ©2012 Serpa Neto et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Serpa Neto, Ary Nassar, Antônio P Cardoso, Sérgio O Manetta, José A Pereira, Victor GM Espósito, Daniel C Damasceno, Maria CT Russell, James A Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials |
title | Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials |
title_full | Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials |
title_fullStr | Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials |
title_full_unstemmed | Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials |
title_short | Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials |
title_sort | vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580743/ https://www.ncbi.nlm.nih.gov/pubmed/22889256 http://dx.doi.org/10.1186/cc11469 |
work_keys_str_mv | AT serpanetoary vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials AT nassarantoniop vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials AT cardososergioo vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials AT manettajosea vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials AT pereiravictorgm vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials AT espositodanielc vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials AT damascenomariact vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials AT russelljamesa vasopressinandterlipressininadultvasodilatoryshockasystematicreviewandmetaanalysisofninerandomizedcontrolledtrials |